A rundown of new bibliographies & research guides

The research base spans many disciplines and goes back almost 50 years. To help researchers get oriented, an on-ramp was added. In the Systems & functions area, a new bibliography was added: Adverse effects on skin, comprising nine case reports. The gynecomastia bibliography has been expanded. The bibliography on the musculoskeletal system has been expanded … Read more

2022 – year in review

Regulators added warnings, the New York Post covered finasteride harms, and two influencers urged followers to avoid the drug 1. In the long war over finasteride safety, social taboos around sexuality and mental state have played an important, but overlooked role. Read about their role in this post: From the depths: why finasteride harms took … Read more

Recent developments

In June 2022, the FDA required the addition of ‘suicidal ideation and behavior’ to the Propecia (finasteride 1 mg) label. In July, France’s national drug regulator ANSM added materials to help patients better understand the risks of finasteride.

FDA quashed internal warning on suicidality linked to Propecia; changed course in 2022

KEY POINTS In 2010, Merck requested to add ‘depression’ to adverse events in the Propecia label. A safety group within FDA concurred, and also recommended adding ‘suicidal thoughts and behavior.’ FDA’s dermatology products group did not support adding a suicidality warning. Only ‘depression’ was added to the label in 2011. Over a decade later, in … Read more

News – August 2021

SUMMARY The Sexual Medicine Society of North America hosted a webinar including a talk about sexual dysfunction induced by finasteride and SSRIs. A study by Baylor researchers finding altered gene expression in post-finasteride patients was published in the Journal of Sexual Medicine. The FDA added a new adverse event to the Propecia label: Hematospermia. The … Read more